john william codling (@youngcodling) header
john william codling (@youngcodling) profile picture

artist-nyc

Manhattan, NY
Joined May 2009
Can I get a RT @JHarden13 @asunews @asufoundation @ASU @trvisXX #ArizonaState #johncodling @AdamLefkoe ♥️♥️♥️♥️♥️♥️♥️♥️♥️♥️
13
31
john william codling retweeted
This needs approved like YESTERDAY!! Let’s go !! We don’t have time to wait .
1
1
34
john william codling retweeted
NVG-291 is the only drug ever shown in a clinical trial to repair spinal cord nerve in people. Here’s how to watch my original report on Full Measure Sunday: Fullmeasure.news
3
11
1
33
1,617
john william codling retweeted
The finish line is still ahead. The next step is to work with insurers to get the drug paid for. Link: u2fp.org/get-educated/articl… #spinalcordinjury #scirecovery #spinalcordresearch #scirehabilitation #sciadvocacy
1
5
1
11
193
Red Bull's Wings for Life has funded spinal cord research for years. Now NVG-291 has FDA Breakthrough Therapy designation for chronic SCI. Dennis Prager's story airs Sunday 10:30am ET 👇 @redbull @WFLWorldRun @redbullracing @Max33Verstappen @yukitsunoda07 @RyanShazier @TrentAA @scottyjames @danielaryf @LoicBruni open.spotify.com/episode/5CY…
2
160
Big news for spinal cord injury: the FDA granted NervGen's NVG-291 Breakthrough Therapy designation. Hear Dennis Prager on why it matters 👇 Full TV program airs Sunday at 10:30am ET. #SCI #SpinalCordInjury open.spotify.com/episode/5CY… globenewswire.com/news-relea…
2
6
202
Newsrooms: NVG-291 just got FDA Breakthrough Therapy designation for spinal cord injury. Dennis Prager's story airs Sunday 10:30am ET on Full Measure. @DennisPrager @prageru @cnnhealth @NBCNewsHealth @foxnewshealth @FoxNews @nypost @NewsNation @axios @BioPharmaDive @medpagetoday
76
Dennis Prager was paralyzed in a fall. Now he's one of thousands pushing for faster access to NVG-291, a potential spinal cord injury treatment. @elonmusk should buy NervGen. 👇 #SCI #SpinalCordInjury #Paralysis open.spotify.com/episode/5CY…
1
5
158
john william codling retweeted
Here's a look at whats ahead this week on Full Measure. Watch Full Measure Sunday: Fullmeasure.news
2
3
1
20
1,581
john william codling retweeted
🚨Big news in spinal cord injury research. NVG-291 (from NervGen) just received FDA Breakthrough Therapy Designation for chronic traumatic cervical motor-incomplete SCI. After a spinal cord injury, scar tissue releases molecules called CSPGs that act like a “stop” signal, blocking nerves from regrowing or reconnecting...even years later. NVG-291 is a peptide (given by daily under-the-skin injection) designed to interrupt that stop signal at the PTPσ receptor so the nervous system has a better chance to repair itself. In the Phase 1b/2a CONNECT SCI study, people with chronic incomplete cervical injuries showed meaningful gains in hand function (measured by GRASSP Quantitative Prehension), electrophysiological signaling, and reported improvements in everyday independence and quality of life compared with placebo. It was generally well tolerated. This designation recognizes the potential for substantial improvement over existing options and can speed development. The Phase 3 RESTORE trial is now enrolling (~150 participants in the US and Canada) to confirm these findings. Primary endpoint is hand function. Still investigational...not approved yet...but it’s one of the most promising pharmacologic approaches we’ve seen aimed at actual neural repair in chronic SCI. nervgen.com/nervgen-receives… #SpinalCordInjury #SCI #NerveRegeneration #NVG291 #BreakthroughTherapy #FromHollywoodToQuadriplegic #NeuroRepair #Quadriplegia #Hope
2
2
23
613
john william codling retweeted
NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury by @GlobeNewswire ceo.ca/@GlobeNewswire/nervge… "Breakthrough Therapy designation is a process designed to expedite the development and review of drugs that are intended to treat a serious condition for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on one or more clinically significant endpoints. The benefits of Breakthrough Therapy designation include eligibility for Priority Review, rolling submission of sections of the New Drug Application and FDA’s organizational commitment to help determine an efficient route to approval."
2
2
12
561
john william codling retweeted
I bought NGEN yesterday and I’m up almost 20%. NervGen pharma has a new peptide that fixes spinal cord injuries, it got breakthrough status from the FDA yesterday.
1
2
887
john william codling retweeted
While investors panic about AI, there's a peptide that literally seems to cure spinal chord injury We're going to make so much money with AI<>Biology
Niko was left quadriplegic after a car accident. He lost hand, triceps, bowel, bladder and sexual function, facial movement, and blood pressure and temperature regulation. After taking $NGEN’s NVG-291 peptide for 12 weeks, he reportedly regained much of that function. Bio/Acc. Disclaimer: I don't have a position on $NGEN.
7
18
1
251
32,186
john william codling retweeted
Replying to @alc2022
Amazing! Our son is quad. No finger movement. We are anxiously watching NVG-291 phase 3. What is frustrating is we have a drug that has been proven safe and getting amazing results and yet is taking forever to go through trials. Our son and many others need this peptide!
1
1
8
321
Replying to @alc2022
I love hearing these stories. I understand why it takes so long, but I'm dying for phase 3 to be finished and see how the drug works in so many more people.
1
7
507